Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
76.99
+0.54 (0.71%)
Aug 12, 2026, 9:10 AM EDT - Market open
Cytokinetics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -894 | -784.96 | -589.53 | -526.24 | -388.96 | -215.31 |
Depreciation & Amortization | 12.55 | 10.13 | 9.53 | 11.89 | 5.81 | 2.28 |
Stock-Based Compensation | 127.31 | 112.29 | 97.84 | 72.07 | 47.85 | 26.83 |
Other Adjustments | 82.35 | 188.21 | 50.56 | 25.07 | 60.48 | 35.23 |
Change in Receivables | -16.02 | -1.11 | -15.37 | -1.14 | 56.67 | -47.4 |
Changes in Inventories | -5.82 | - | - | - | - | - |
Changes in Accounts Payable | 7.84 | 2.66 | -4.48 | -3.48 | 4.52 | 1.06 |
Changes in Accrued Expenses | 33.02 | 33.6 | 14.18 | 17.1 | 10.84 | 15.06 |
Changes in Unearned Revenue | 0.31 | -50.76 | 52.37 | - | -87 | - |
Changes in Other Operating Activities | -24.1 | -20.02 | -11.04 | -9.4 | -9.74 | 39.74 |
Operating Cash Flow | -555.45 | -510.01 | -395.89 | -414.33 | -299.52 | -142.52 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Capital Expenditures | -25.26 | -24.81 | -3.91 | -1.42 | -11.34 | -48.87 |
Purchases of Investments | -1,515 | -1,068 | -1,293 | -635.21 | -855.39 | -525.04 |
Proceeds from Sale of Investments | 1,036 | 1,110 | 744.23 | 875.88 | 604.59 | 426.14 |
Investing Cash Flow | -503.68 | 16.67 | -553.1 | 239.25 | -262.13 | -147.78 |
Long-Term Debt Issued | -729.46 | - | 729.46 | - | 523.59 | - |
Long-Term Debt Repaid | -11.76 | -413.31 | -8.68 | - | -187.98 | - |
Net Long-Term Debt Issued (Repaid) | -741.22 | -413.31 | 720.78 | - | 335.61 | - |
Issuance of Common Stock | 1,394 | 649.18 | 146.66 | 182.69 | 17.54 | 324.43 |
Repurchase of Common Stock | -4.27 | -2.47 | -19.63 | -10.52 | -9.6 | -4.45 |
Net Common Stock Issued (Repurchased) | 1,390 | 646.72 | 127.03 | 172.18 | 7.94 | 319.98 |
Other Financing Activities | 100 | 174.8 | 199.06 | 49.14 | 172.62 | - |
Financing Cash Flow | 1,242 | 524.46 | 930.61 | 221.32 | 516.17 | 319.98 |
Foreign Exchange Rate Adjustments | -0.84 | -0.72 | 0.21 | -0.02 | - | - |
Net Cash Flow | 181.83 | 30.4 | -18.17 | 46.22 | -45.48 | 29.68 |
Free Cash Flow | -580.72 | -534.82 | -399.8 | -415.75 | -310.85 | -191.39 |
Free Cash Flow Growth | - | - | - | - | - | - |
FCF Margin | -858.16% | -607.48% | -2164.10% | -5521.24% | -328.64% | -271.76% |
Free Cash Flow Per Share | -4.67 | -4.45 | -3.57 | -4.31 | -3.46 | -2.49 |
Levered Free Cash Flow | -1,637 | -1,247 | 187.91 | -511.54 | -140.25 | -206.06 |
Unlevered Free Cash Flow | -709.38 | -661.45 | -479.59 | -481.5 | -411.1 | -177.05 |